Suggested recent literature

Articles found by an AI-assisted PubMed search that may be missing from CancerImmunoDB, shared so that curators and users can see what is being considered.

These articles are not part of the database yet. Each one is a suggestion. The AI judged it from the title and abstract only and can be wrong. A curator reads the full paper, and only then is it added to CancerImmunoDB. A column on this page shows the curators' decision as soon as there is one.

How the list is made

  1. Search. For every year from 2021 to 2026, PubMed is searched for primary research on cancer drugs together with immune terms, and the 100 best matches of each year are taken. Every PubMed ID comes from PubMed itself, never from the AI.
  2. AI screening. Google Gemini reads each title and abstract and says whether the study tests a named anticancer drug and measures its effect on the immune system, the same scope as the database. In a first check, it marked 33 of 40 articles that curators had already accepted as likely relevant (and 1 as uncertain), and it rejected all 20 unrelated cancer articles.
  3. Curator check. Curators read each suggested paper in full and decide. Accepted papers are entered into the database with their doses, techniques and immune terms.

Why this exists: the database holds only about 10 articles a year for 2021–2024, and a plain PubMed search cannot judge whether a paper fits the scope.

574articles screened
360likely relevant
11uncertain
203not relevant
0checked by a curator
0accepted into the database
YearScreenedLikely relevant
20269961
202510081
20249872
20239245
202210052
20218549

Browse the suggestions

Reset Download the full list (CSV)

360 articles shown. “In the database” counts the entries the database already has for each drug the AI named (cell line / animal / patient).

PMIDYearArticleDrugsStudy typeCancer typeIn the databaseCurator status
36131607 2022 Resveratrol reduces lactate production and modifies the ovarian cancer immune microenvironment. Neoplasma Likely relevant The study tests resveratrol and PD-1 blockade in vitro and in vivo, measuring effects on lactate production, Treg suppressive function, and anti-tumor immunity. resveratrol; PD-1 blockade Mixed ovarian cancer resveratrol 8/0/0; PD-1 blockade 0/0/0 Awaiting curator check
36159865 2022 Immune-related RNA signature predicts outcome of PD-1 inhibitor-combined GEMCIS therapy in advanced intrahepatic cholangiocarcinoma. Frontiers in immunology Likely relevant The study assays immunogenic properties of gemcitabine-based chemotherapy and evaluates immune-related molecules using multiplexed immunofluorescence and flow cytometry in patients treated with GEMCIS and sintilimab. gemcitabine; cisplatin; sintilimab Patient advanced intrahepatic cholangiocarcinoma gemcitabine 30/23/10; cisplatin 18/3/11; sintilimab 0/0/1 Awaiting curator check
36165836 2022 Reshaping hypoxia and silencing CD73 via biomimetic gelatin nanotherapeutics to boost immunotherapy. Journal of controlled release : official journal of the Controlled Release Society Likely relevant The study tests biomimetic gelatin nanotherapeutics delivering CD73siRNA combined with PD-L1 blockade in mouse models and measures immune cell populations and cytokines. CSG@B16F10; CD73siRNA; PD-L1 checkpoint blockade Animal melanoma CSG@B16F10 0/0/0; CD73siRNA 0/0/0; PD-L1 checkpoint blockade 0/0/0 Awaiting curator check
36243711 2022 TiSe2-mediated sonodynamic and checkpoint blockade combined immunotherapy in hypoxic pancreatic cancer. Journal of nanobiotechnology Likely relevant Tests TiSe2-mediated sonodynamic therapy combined with anti-PD-1 in mice and measures immune cell infiltration, cytokine secretion, and DC maturation. TiSe2 nanosheets; anti-PD-1 Animal pancreatic cancer TiSe2 nanosheets 0/0/0; anti-PD-1 14/36/0 Awaiting curator check
36256824 2022 FLASH X-ray spares intestinal crypts from pyroptosis initiated by cGAS-STING activation upon radioimmunotherapy. Proceedings of the National Academy of Sciences of the United States of America Likely relevant Tests radioimmunotherapy combining FLASH X-ray and anti-PD-L1 in mice, evaluating CD8+ T cell-mediated immune responses and cGAS-STING activation. anti-PD-L1 Animal unspecified anti-PD-L1 0/15/0 Awaiting curator check
36263619 2022 PD‑L1 mediates triple‑negative breast cancer evolution via the regulation of TAM/M2 polarization. International journal of oncology Likely relevant Tests alpha-PD-L1 in vitro and in vivo, measuring its effect on TAM/M2 polarization and STAT3 signaling. alpha-PD-L1 Mixed triple-negative breast cancer alpha-PD-L1 0/0/0 Awaiting curator check
36288869 2022 Development of Novel Small Antitumor Compounds Inhibiting PD-1/PD-L1 Binding. Anticancer research Likely relevant The study tests novel small molecule inhibitors of PD-1/PD-L1 in vivo using a humanized mouse model and assesses CD8+ T cell infiltration. SCL-1; SCL-2; anti-PD-1 antibody Animal squamous cell carcinoma SCL-1 0/0/0; SCL-2 0/0/0; anti-PD-1 antibody 0/2/0 Awaiting curator check
36322632 2022 Targeting cancer glycosylation repolarizes tumor-associated macrophages allowing effective immune checkpoint blockade. Science translational medicine Likely relevant The study tests an antibody-sialidase conjugate and immune checkpoint blockade in murine models, demonstrating macrophage repolarization and enhanced adaptive antitumor immunity. antibody-sialidase conjugate; immune checkpoint blockade (ICB) Animal cancer antibody-sialidase conjugate 0/0/0; immune checkpoint blockade (ICB) 0/0/0 Awaiting curator check
36333531 2022 Reprogramming of pancreatic adenocarcinoma immunosurveillance by a microbial probiotic siderophore. Communications biology Likely relevant Tests ferrichrome and anti-PD-L1 in a mouse model and measures macrophage reprogramming and CD8+ T cell infiltration. ferrichrome; anti-PD-L1 Animal pancreatic cancer ferrichrome 0/0/0; anti-PD-L1 0/15/0 Awaiting curator check
36372138 2022 Combination of photosensitizer and immune checkpoint inhibitors for improving the efficacy of tumor immunotherapy. International journal of pharmaceutics Likely relevant The study tests a combination of photosensitizer and immune checkpoint inhibitor delivery systems and measures immune cell activation and pathway blockade. PD-L1McAb&HMME@Clip; immune checkpoint inhibitors Unclear tumors PD-L1McAb&HMME@Clip 0/0/0; immune checkpoint inhibitors 0/0/0 Awaiting curator check
36713444 2022 Releasing the restraints of Vγ9Vδ2 T-cells in cancer immunotherapy. Frontiers in immunology Likely relevant The study experimentally tests zoledronic acid and Bacillus Calmette-Guérin on Vγ9Vδ2 T-cells and tumour cell co-cultures, measuring checkpoint receptor expression, cytotoxicity, and cytokine production. zoledronic acid; Bacillus Calmette-Guérin Cell line unspecified tumour cell targets zoledronic acid 0/0/0; Bacillus Calmette-Guérin 0/0/0 Awaiting curator check
33046519 2021 Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling. Clinical cancer research : an official journal of the American Association for Cancer Research Likely relevant Evaluates combinations of the SHP2 inhibitor TNO155 and other targeted/immunotherapy drugs in vitro and in vivo, reporting effects on tumor-associated macrophages. TNO155; nazartinib; BRAF inhibitor; MEK inhibitor; KRASG12C inhibitor; ribociclib; anti-PD-1 antibody Mixed lung and colorectal cancer TNO155 0/0/0; nazartinib 0/0/0; BRAF inhibitor 0/2/2; MEK inhibitor 21/5/1 Awaiting curator check
33144318 2021 Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma. Gut Likely relevant Tests cabozantinib, MLN0128, and anti-PD-L1 in cell lines and mouse models, assessing tumor-infiltrating T cells and PD-L1 expression. cabozantinib; MLN0128; anti-PD-L1 antibody Mixed hepatocellular carcinoma cabozantinib 15/4/1; MLN0128 0/0/0; anti-PD-L1 antibody 0/1/0 Awaiting curator check
33257429 2021 Modification of Extracellular Matrix Enhances Oncolytic Adenovirus Immunotherapy in Glioblastoma. Clinical cancer research : an official journal of the American Association for Cancer Research Likely relevant The study experimentally tests oncolytic adenoviruses and anti-PD-1 checkpoint blockade in murine orthotopic glioblastoma and reports their effects on tumor-infiltrating immune cells and T-cell cytotoxicity. ICOVIR17; ICOVIR15; anti-PD-1 Animal glioblastoma ICOVIR17 0/0/0; ICOVIR15 0/0/0; anti-PD-1 14/36/0 Awaiting curator check
33276030 2021 CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma. Journal of hepatology Likely relevant Tests CD40 agonist, anti-PD-1, and chemotherapy in murine CCA models and measures immune cell infiltration and activation via FACS. IgG control; CD40 agonistic antibody; anti-PD-1; gemcitabine; cisplatin Animal intrahepatic cholangiocarcinoma IgG control 0/0/0; CD40 agonistic antibody 0/0/0; anti-PD-1 14/36/0; gemcitabine 30/23/10 Awaiting curator check
33311600 2021 Anti-PD-L1 mediating tumor-targeted codelivery of liposomal irinotecan/JQ1 for chemo-immunotherapy. Acta pharmacologica Sinica Likely relevant The study experimentally tests liposomal irinotecan/JQ1 codelivery targeted with anti-PD-L1 in tumor-bearing mice and measures immune readouts such as DC maturation, CD8+ T cells, IFN-gamma, and Tregs. irinotecan; JQ1; anti-PD-L1 Animal colorectal cancer irinotecan 30/2/0; JQ1 14/6/0; anti-PD-L1 0/15/0 Awaiting curator check
33320838 2021 Ketogenic diet and ketone bodies enhance the anticancer effects of PD-1 blockade. JCI insight Likely relevant The study evaluates ketogenic diet/3-hydroxybutyrate and checkpoint blockade in mice, measuring changes in PD-L1 expression on myeloid cells and CXCR3+ T cell expansion. anti-PD-1; anti-CTLA-4; 3-hydroxybutyrate Animal general tumors anti-PD-1 14/36/0; anti-CTLA-4 1/10/7; 3-hydroxybutyrate 0/0/0 Awaiting curator check
33338425 2021 DNA Sensing in Mismatch Repair-Deficient Tumor Cells Is Essential for Anti-tumor Immunity. Cancer cell Likely relevant The study evaluates anti-PD-1 therapy in tumor models, assessing cytosolic DNA sensing, IFN-beta production, and T cell infiltration. anti-PD-1 Animal mismatch repair-deficient cancer anti-PD-1 14/36/0 Awaiting curator check
33357452 2021 Immunogenic Chemotherapy Enhances Recruitment of CAR-T Cells to Lung Tumors and Improves Antitumor Efficacy when Combined with Checkpoint Blockade. Cancer cell Likely relevant The study tests chemotherapy (cyclophosphamide, oxaliplatin) and checkpoint blockade (anti-PD-L1) in a mouse lung cancer model, measuring effects on CAR-T cell infiltration and macrophage activation. cyclophosphamide; oxaliplatin; anti-PD-L1 Animal lung adenocarcinoma cyclophosphamide 5/15/9; oxaliplatin 12/5/2; anti-PD-L1 0/15/0 Awaiting curator check
33408092 2021 Skin dendritic cells in melanoma are key for successful checkpoint blockade therapy. Journal for immunotherapy of cancer Likely relevant The study experimentally tests Flt3L, polyI:C, anti-CD40, anti-PD-1, and anti-TIM-3 in tumor-bearing mice and measures their effects on dendritic cells, T cell numbers, activation, checkpoint expression, and cytokine production. Fms-related tyrosine 3 ligand; polyI:C; anti-CD40; anti-PD-1; anti-TIM-3 Animal melanoma Fms-related tyrosine 3 ligand 0/0/0; polyI:C 0/0/0; anti-CD40 7/5/0; anti-PD-1 14/36/0 Awaiting curator check
33421711 2021 Phenolic immunogenic cell death nanoinducer for sensitizing tumor to PD-1 checkpoint blockade immunotherapy. Biomaterials Likely relevant Tests a phenolic ICD inducer nanoparticle containing doxorubicin in tumor-bearing models and evaluates immune cell infiltration and maturation. doxorubicin Animal tumor models doxorubicin 22/9/0 Awaiting curator check
33453147 2021 Inhibition of vascular adhesion protein-1 enhances the anti-tumor effects of immune checkpoint inhibitors. Cancer science Likely relevant The study experimentally tests a vascular adhesion protein-1 inhibitor (U-V296) and immune checkpoint inhibitors in murine colon cancer models and measures multiple immune cell populations, cytokines, and T cell functions. U-V296; immune checkpoint inhibitors Animal colon cancer U-V296 0/0/0; immune checkpoint inhibitors 0/0/0 Awaiting curator check
33462141 2021 Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer. Journal for immunotherapy of cancer Likely relevant The study tests antibodies targeting IL-17A and PD-1 in mouse models and examines their effects on CD8+ T cells, PD-L1 levels, and myeloid-derived suppressor cells. anti-IL-17A; anti-PD-1 Mixed colorectal cancer anti-IL-17A 0/0/0; anti-PD-1 14/36/0 Awaiting curator check
33502118 2021 Cancer-on-a-Chip for Modeling Immune Checkpoint Inhibitor and Tumor Interactions. Small (Weinheim an der Bergstrasse, Germany) Likely relevant Tests anti-PD-1 antibodies on cancer spheroids and T cells in a microfluidic device, measuring T cell infiltration and IL-2 secretion. anti-PD-1 Cell line breast cancer anti-PD-1 14/36/0 Awaiting curator check
33504617 2021 Blockade of PD-1/PD-L1 Pathway Enhances the Antigen-Presenting Capacity of Fibrocytes. Journal of immunology (Baltimore, Md. : 1950) Likely relevant Examines the function of human and murine fibrocytes and demonstrates that PD-L1 blockade enhances CD8+ T cell proliferation. anti-CD86; anti-CD54; anti-PD-L1 Mixed lung adenocarcinoma anti-CD86 0/0/0; anti-CD54 0/0/0; anti-PD-L1 0/15/0 Awaiting curator check
← Previous Page 13 of 15 Next →